Search

Displaying results 3471 - 3480 of 4236 in total
  1. Drug

    PF-06291874

    go.drugbank.com/drugs/DB15065
    Investigational

    PF-06291874 is under investigation in clinical trial NCT02175121 (Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study of PF-06291874 as Oral Monotherapy To Treat Adults With Type 2 Diabetes

  2. Drug

    Bismuth subsalicylate

    go.drugbank.com/drugs/DB01294
    ApprovedVet approved

    Bismuth subsalicylate is an antacid and anti-diarrheal agent. Exhibiting antibacterial and gastroprotective properties, bismuth subsalicylate is an insoluble salt of salicylic acid linked to trivalent bismuth cation. Each molecule of bis...

    Products: Bismylate-bismuth Subsalicylate Sus 17.6gm/ml
  3. Drug

    Captopril

    go.drugbank.com/drugs/DB01197
    ApprovedInvestigational

    Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the r...

  4. Drug

    VA-MENGOC-BC®

    go.drugbank.com/drugs/DB15800
    Experimental

    As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials. … Novel antigens such as γ-glutamyltranspeptidase, exopolyphosphatase, and a cell-binding factor protein were also identified with administration of this vaccine by a study.

  5. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. … In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability

  6. Drug

    Tosedostat

    go.drugbank.com/drugs/DB11781
    Investigational

    It has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and in synergy with cytotoxic agents such as carboplatin and paclitaxel.

  7. Drug

    Ginsenoside Rg1

    go.drugbank.com/drugs/DB06750
    ExperimentalNutraceutical

    Ginsenosides have been the target of research, as they are viewed as the active compounds behind the claims of ginseng's efficacy.

  8. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. … It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha.

  9. Drug

    Melperone

    go.drugbank.com/drugs/DB09224
    Investigational

    Recently, it has been studied as a treatment of psychosis related to Parkinson's disease [L1316]. … It has been well established in the treatment of confusion, anxiety, restlessness (particularly in the elderly) and schizophrenia as It is known to be well-tolerated with an excellent safety profile.

  10. Drug

    Esmolol

    go.drugbank.com/drugs/DB00187
    ApprovedInvestigationalWithdrawn

    Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing acti...